RSV Seasonal Vaccine Introduction and Growth Strategy

2023 full year outlook considerations to support modelling Vaccines turnover Increase mid-teens %, excluding pandemic adjuvant sales Shingrix to increase high-teens % Flu to decrease around 20% Meningitis to increase mid to high-teens % Established Vaccines to increase high single-digit % Turnover to adj. operating profit items COGS: to increase at a rate broadly aligned to turnover SG&A: to increase at a rate broadly aligned to turnover R&D: to increase at a rate slightly below turnover Royalties: around £800m GSK adj. operating profit is expected to increase between 11% and 13% The above items exclude the impact of COVID-19 solutions Specialty Medicines turnover Increase high single-digit % for Specialty Medicines, excluding Xevudy sales HIV to increase high single-digit % Oncology to decrease mid-teens %, before returning to growth in 2024 Adj. operating profit to adj. EPS items Interest: between £700m to £750m Share of associates: negligible Tax rate: around 15% Non-controlling interest: ViiV is main ongoing NCI, with Q1 2022 'Other' NCI not repeating GSK adj. EPS is expected to increase between 14% and 17% General Medicines turnover Increase low single-digit % COVID-19 solutions Not anticipating significant sales Expect this to reduce GSK turnover growth by approximately 8% and reduce adj. operating profit growth by 4% to 5% Dividend Expect 56.5p per share GSK All turnover and growth comments at CER. Adj. is abbreviation for Adjusted. All expectations and targets regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on page 54 of our second quarter 2023 earnings release, page 2 of our second quarter 2023 results announcement and the cautionary statement slide included with this presentation. Tax rate expectation is based on enacted legislation and is reflective of the anticipated performance of the business and key assets. The tax rate could fluctuate in individual years due to the timings of settlements of open years with tax authorities, as we continuously bring our tax affairs up to date. Interest expectation assumes no significant adverse movements in interest rates. 33 33

View entire presentation